SARS-CoV-2流行期间癌症患者治疗选择的临时指南

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)肺炎(新冠肺炎)的流行,对癌症患者的治疗是灾难性的挑战。癌症患者与SARS-CoV-2感染的临床特异性数据非常有限,我们基于医学文献和相关网站搜索的证据,通过广泛讨论,结合湖北省肿瘤医院的实际,为癌症患者,尤其是新冠病毒(COVID-19)感染后恢复的癌症患者,就其手术、放化疗、靶向治疗、免疫治疗等方案的制定以及临床研究参与者的工作实施问题达成了临时指南,供临床参考和实践。本指南尤其强调以下原则:多学科团队,治疗前风险与获益的评估,个体化满足患者的医学需求,伦理和患者的社会经济条件。

Interim Guideline for Treatment Options on Cancer Patients During SARS-CoV-2 Pandemic

In the current pandemic of SARS-Cov-2 (formally known as novel coronavirus disease 2019, COVID-19), the cancer treatment is particularly a challenge that must be overcome as soon as possible. Currently, the clinical data on the prevalence of SARS-Cov-2 in cancer patients is very limited, alone with constant evolving situations. To obtain existing evidence, we reviewed a wide range of medical literature and relevant websites including the National Health Commission of China. With the actual situation of Hubei Cancer Hospital, we formulated the interim guideline which was developed by all contributors from different disciplines after fully discussion, to provide the reference for treatment options on cancer patients, especially the cancer patients recovered from COVID-19 infection. This guideline highlighted the multidisciplinary team (MDT) diagnostic model, the assessment between risks and benefits prior to treatment, individualized service for patients’ medical needs, and the acceptability in ethics and patients’ socio-economic conditions.